Medical news of portal is the most update information on pharmaceutical and medical equipment market



The periodical about the pharmaceutical and medical equipment markets


(Russian pharmacies) - specialized periodical edition for pgarmacy professionals


Medical Council - Scientific Journal for Physicians

Home / News


R-Pharm continues to dominate in segment of public procurements in Russia

R-Pharm, one of Russia’s leading drugmakers, has won the 1 billion roubles (~$16 million) tender for the supplies of its teriflunomide drug for state needs, according to the company, reports The Pharma Letter’s local correspondent.

The tender was conducted without other bidders, which again sparks concerns of some Russian analysts of the affiliation of the company with the Russian Ministry of Health.

Teriflunomide, the active ingredient of French pharma major Sanofi’s (Euronext: SAN) Aubagio, is a drug, used to treat multiple sclerosis. This is the only new drug included in the program of seven high-cost nosologies, a state program in Russia that involves purchases of the most expensive drugs for state needs.

The company will supply the drug under the Abadzhio brand, which is produced by Sanofi subsidiary Genzyme, and is packed by R-Pharm. Under the terms of the agreement, the distributor must supply 10.2 million packs of the drug until September 1, 2018.

R-Pharm became the only participant in the auction, although in February 2017, Valenta Farm registered its Femoriks generic, however, for some reason, was refused from the participation in the tender with its drug.

Valenta Farm is not the first drugmaker in Russia which created a generic, but was not able to participate in the tender.

In 2017, Farmasintez registered the Kalidavir drug - the first generic Kaletra - an original drug, which is produced by AbbVie, one of the most sought-after anti HIV drugs purchased under the state program (lopinavir + ritonavir). In 2017, the Ministry of Health spent more than 5 billion roubles on its purchase, with all contracts signed with the R-Pharm. This year, the Ministry has already held three auctions for the supply of this drug, the winners of which was R-Pharm, which signed contracts for 1.2 billion roubles.

In March of the current year, the Russian Federal Anti-Monopoly Service started an investigation on the suspicious of R-Pharm in collusion with the Ministry of Health, so that the company could get benefits during public procurements. A subject of the investigation became 19 contracts worth 8.2 billion roubles for the supply of antiviral drugs. At that time both the Health Ministry and the company denied accusations of the FAS.


Remedium group


publishing house


programmer of electronic software products


advertisement agency


rent-a-rep company